Abstract Background The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3-mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce. Methods Clinical data are reported from 394 ND… Continue reading Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
Tag: Leukemia and Lymphoma
Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein
Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma
Adult T-cell leukemia/lymphoma (ATLL), an aggressive T-cell malignancy associated with human T-cell leukemia virus type 1, presents significant therapeutic challenges due to high relapse rates and resistance to therapy. Here, we present the first reported case of ATLL treated with talimogene laherparepvec (T-VEC), an oncolytic viral immunotherapy approved for unresectable melanoma. The patient, who had… Continue reading Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma
Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?
Phase 3 randomized controlled trials (RCTs) are pivotal to the advancement of clinical care and scientific decision-making in clinical oncology.1 In RCTs, setting an appropriate primary endpoint is fundamental to maximizing the validity, reproducibility, and clinical applicability of trial results. The primary endpoint may differ depending on the patients included or modality of the treatment evaluated;… Continue reading Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?
Enrichment of CD7+CXCR3+ CAR T cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma
Chimeric antigen receptor (CAR) T-cell therapy is the standard of care for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, more than half of patients fail to achieve durable remission. Identifying predictive biomarkers within the CAR T-cell infusion product (IP) may guide strategies to improve clinical outcomes.
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
Abstract Background Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B-cell acute lymphoblastic leukemia (B-ALL) but real-world data are limited. Methods The INO-CD22 study is a multicenter retrospective cohort study of adult patients with relapsed/refractory B-ALL treated with IO in 24 Italian centers from 2014 to 2019, with the aim of assessing… Continue reading INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
Nursery of the blood: How stem cells calm the body’s immune response
Our blood consists of many cell types that develop through different stages from a precursor type — the blood stem cell. An international research team has now investigated the developmental pathways of blood cells in humans. The results yielded a surprise: Even stem cells possess surface proteins that enable them to suppress the activation of… Continue reading Nursery of the blood: How stem cells calm the body’s immune response
New function discovered for protein important in leukemia
In addition to exporting materials out of the nucleus, the protein, called Exportin-1 (also called Xpo1 or Crm1), seems to play a role in promoting gene transcription, the process that creates RNA replicas of strands of DNA to express genes.
[ASAP] Discovery of Novel SIK2/3 Inhibitors for the Potential Treatment of MEF2C+ Acute Myeloid Leukemia (AML)
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Abstract Focused research in acute myeloid leukemia (AML) biology and treatment has led to the identification of new therapeutic targets and several new drug approvals over the last decade. Progressive improvements in response and survival have mirrored these improvements in treatment options. Traditionally adverse subtypes such as FLT3–internal tandem duplication–positive AML now have better outcomes… Continue reading Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges